Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MR901 in Patients With LUTS Due to BPH
NCT02326454Phase 2Completed
- Sponsor
- Light Science Oncology
- Start
- Nov 2014
- Primary completion
- Mar 2017
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of talaporfin sodium in benign prostatic hyperplasia (BPH) (4 arms), sponsored by Light Science Oncology. Primary endpoint: International Prostate Symptoms Score at 12 weeks. Started Nov 2014; status: completed.
02
Drugs
talaporfin sodium
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT02326454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02326454.